The reasons are simple - 1) Less price erosion than US generics many ROW markets operate on tender-based or branded-generic models with less competitive intensity 2) Higher entry barriers than domestic Indiarequires regulatory filings (EU GMP, WHO PQ, ANVISA), distribution infrastructure, and local market knowledge 3) Branded potential - unlike the US where generics are interchangeable, many ROW markets allow branded generics that can command premium pricing 4) Large unmet need - healthcare access in Africa, LatAm, and Southeast Asia is expanding, creating genuine volume growth (not just market share battles) Lets see who is doing well here - 13) Strides Pharma - The Ex-US Transformation Story + Controlled drug substances Strides transformation from a US-centric generics player to a diversified international formulator is one of the most underappreciated stories in Indian pharma
Check your pharmacy label first
Patients experiencing GLP-1 digestion issues may notice bloating, infrequent bowel movements, or abdominal discomfort-especially during the first few weeks or when doses increase
Patent Expiry: The date when the legal protection for an invention (like a drug) ends, allowing other companies to produce generic versions
Food companies are targeting consumers on weight-loss drugs with new GLP-1-friendly entres loaded with lean protein and fiber
Reviews are mixed: early animal and small human trials show clear deltawave enhancement, while larger controlled studies have yielded inconsistent results, leaving DSIP classified as experimental Delta sleepinducing peptide Reviews